AN2 Therapeutics, Inc. Share-based Payment Arrangement, Expense
AN2 Therapeutics, Inc. (ANTX) reported Share-based Payment Arrangement, Expense of $972.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $972.00K, a 51.35% decline year-over-year.
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.46M, a 28.68% decline year-over-year.
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.40M, a 21.35% decline year-over-year.
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $801.00K, a 57.89% decline year-over-year.
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $6.25M, a 25.09% decline from fiscal 2024.
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $8.34M, a 0.88% decline from fiscal 2023.
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $8.41M, a 91.57% increase from fiscal 2022.
- AN2 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $4.39M, a 350.82% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $972.00K 10-Q · filed 2026-08-11 | $2.43M 10-Q · filed 2026-08-11 | $3.83M derived: sum of 3 quarters · filed 2026-08-11 | $4.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.46M 10-Q · filed 2026-05-11 | $2.86M derived: sum of 2 quarters · filed 2026-05-11 | $3.66M derived: sum of 3 quarters · filed 2026-05-11 | $5.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.20M derived: sum of 2 quarters · filed 2026-03-17 | $4.20M derived: sum of 3 quarters · filed 2026-08-11 | $6.25M 10-K · filed 2026-03-17 |
| 2025-09-30 | $801.00K 10-Q · filed 2025-11-12 | $2.80M derived: sum of 2 quarters · filed 2026-08-11 | $4.85M 10-Q · filed 2025-11-12 | $6.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-11 | $4.04M 10-Q · filed 2026-08-11 | $5.83M derived: sum of 3 quarters · filed 2026-08-11 | $7.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.05M 10-Q · filed 2026-05-11 | $3.83M derived: sum of 2 quarters · filed 2026-05-11 | $5.73M derived: sum of 3 quarters · filed 2026-05-11 | $8.00M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.68M derived: sum of 2 quarters · filed 2026-03-17 | $5.95M derived: sum of 3 quarters · filed 2026-03-17 | $8.34M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-12 | $4.17M derived: sum of 2 quarters · filed 2025-11-12 | $6.56M 10-Q · filed 2025-11-12 | $8.79M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.27M 10-Q · filed 2025-08-12 | $4.66M 10-Q · filed 2025-08-12 | $6.89M derived: sum of 3 quarters · filed 2025-08-12 | $9.06M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.38M 10-Q · filed 2025-05-13 | $4.62M derived: sum of 2 quarters · filed 2025-05-13 | $6.79M derived: sum of 3 quarters · filed 2025-05-13 | $8.73M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $4.40M derived: sum of 2 quarters · filed 2025-03-25 | $6.34M derived: sum of 3 quarters · filed 2025-03-25 | $8.41M 10-K · filed 2025-03-25 |
| 2023-09-30 | $2.17M 10-Q · filed 2024-11-13 | $4.11M derived: sum of 2 quarters · filed 2024-11-13 | $6.18M 10-Q · filed 2024-11-13 | $7.59M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.94M 10-Q · filed 2024-08-13 | $4.01M 10-Q · filed 2024-08-13 | $5.42M derived: sum of 3 quarters · filed 2024-08-13 | $6.64M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-14 | $3.47M derived: sum of 2 quarters · filed 2024-05-14 | $4.70M derived: sum of 3 quarters · filed 2024-05-14 | $5.94M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $2.70M derived: sum of 2 quarters · filed 2024-03-29 | $3.94M derived: sum of 3 quarters · filed 2024-03-29 | $4.39M 10-K · filed 2024-03-29 |
| 2022-09-30 | $1.23M 10-Q · filed 2023-11-09 | $2.47M derived: sum of 2 quarters · filed 2023-11-09 | $2.92M 10-Q · filed 2023-11-09 | $3.35M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.24M 10-Q · filed 2023-08-10 | $1.69M 10-Q · filed 2023-08-10 | $2.13M derived: sum of 3 quarters · filed 2023-08-10 | $2.48M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $449.00K 10-Q · filed 2023-05-11 | $883.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.24M derived: sum of 3 quarters · filed 2023-05-11 | $1.42M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $787.00K derived: sum of 2 quarters · filed 2023-03-29 | $966.00K derived: sum of 3 quarters · filed 2023-03-29 | $974.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $353.00K 10-Q · filed 2022-11-09 | $532.00K derived: sum of 2 quarters · filed 2022-11-09 | $540.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $179.00K 10-Q · filed 2022-08-11 | $187.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $8.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |